Passage BIO (PASG) Total Current Liabilities (2019 - 2026)
Passage BIO (PASG) posted quarterly Total Current Liabilities of $20.1 million for Q1 2026, up 12.79% year-over-year from $17.8 million in Q1 2025, and down 12.91% quarter-over-quarter from $23.1 million in Q4 2025.
Passage BIO (PASG) Total Current Liabilities (2019 - 2026) Analysis & Trends
Passage BIO's Total Current Liabilities history runs 8 years deep, the most recent figure standing at $20.1 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 12.79% year-over-year to $20.1 million; the TTM figure through Mar 2026 stood at $20.1 million (up 12.79% YoY), while the FY2025 annual figure was $23.1 million, up 19.21% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $20.1 million, down from $23.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $27.5 million in Q1 2022, with the low at $12.4 million in Q2 2024.
- The 5-year median for Total Current Liabilities is $19.8 million (2025), against an average of $19.6 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 37.79% in 2022, then surged 59.88% in 2025.
- Passage BIO's Total Current Liabilities stood at $18.4 million in 2022, then dropped by 10.95% to $16.3 million in 2023, then rose by 18.49% to $19.4 million in 2024, then gained by 19.21% to $23.1 million in 2025, then decreased by 12.91% to $20.1 million in 2026.
- Business Quant data shows PASG's Total Current Liabilities at $20.1 million in Q1 2026, $23.1 million in Q4 2025, and $22.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Passage BIO | 15.05 Mn | 15.05 Mn | - | 20.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.72 Mn |
| Mar 31, 2026 | 20.10 Mn |
| Dec 31, 2025 | 23.08 Mn |
| Sep 30, 2025 | 22.25 Mn |
| Jun 30, 2025 | 19.80 Mn |
| Mar 31, 2025 | 17.83 Mn |
| Dec 31, 2024 | 19.36 Mn |
| Sep 30, 2024 | 16.95 Mn |
| Jun 30, 2024 | 12.39 Mn |
| Mar 31, 2024 | 12.84 Mn |
| Dec 31, 2023 | 16.34 Mn |
| Sep 30, 2023 | 19.81 Mn |
| Jun 30, 2023 | 19.87 Mn |
| Mar 31, 2023 | 17.24 Mn |
| Dec 31, 2022 | 18.35 Mn |
| Sep 30, 2022 | 21.62 Mn |
| Jun 30, 2022 | 27.13 Mn |
| Mar 31, 2022 | 27.48 Mn |
| Dec 31, 2021 | 29.50 Mn |
| Sep 30, 2021 | 22.25 Mn |